Thread by @TheASMR1

Meet our President, A/Prof Christoph Hagemeyer, @cehagemeyer.

As a #nanotechnology expert and #protein #biochemist, his expertise spans across #stroke therapies, improving diagnostic #imaging and targeted #drug #delivery

A thread 👇

@MonashUni @NanobiotechLab

The #2 cause of death worldwide is stroke. Most strokes happen when a blood clot forms and blocks a blood vessel in the brain. Doctors currently use specific therapies that dissolve the clot, allowing blood flow to be returned to the brain, and hopefully, allowing recovery

However, such therapies are associated with severe, sometimes life-threatening adverse bleeding complications. Christoph’s research uses nanotechnology to improve how well this medicine works, while reducing the risk of any side effects.

“The overall goal of our research program is to provide highly specific and targeted to patients that will benefit most. This can be achieved with coupling drugs and diagnostic agents to recombinant antibodies to bring the payload only to the intended area in vivo”.

“After a PhD in fundamental neuroscience research I was interested to work on projects that have high translational potential so my focus shifted to drug delivery and diagnostic molecular imaging”.

Working at the interface between biology and chemistry is exciting: “To drive projects that utilitise the skills + talent of researchers with very diverse backgrounds (engineering, material science, biology, medicine, chemistry) is challenging + highly rewarding at the same time”

Originally completing his PhD in Germany, Christoph was based at a number of prestigious institutes in Europe and Australia (including the @BakerResearchAu), before becoming research lead of the @NanobiotechLab at the Australian Centre for Blood Diseases (@MonashUni)

“With a training background in Chemistry and several postdoctoral years in medical research, I often find myself in the role of an interpreter between the various disciplines working towards the common goal of improving outcomes for patients with the most serious diseases”